http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Feb 2026 07:01:19 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 -0500 ESLA ESLAW http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 -0500 ESLA ESLAW http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 -0500 ESLA ESLAW http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 -0500 ESLA ESLAW http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 -0500 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) completed an $8.0 million registered direct offering and concurrent private placement that closed January 6, 2026, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor. The company also issued common warrants to purchase up to 7,594,935 shares of common stock in the concurrent private placement.</p> <p>The combined offering price was $1.58 per share and accompanying warrant, or $1.57999 for each pre-funded warrant and accompanying warrant. The pre-funded warrants carry an exercise price of $0.00001 per share and are exercisable immediately http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html Tue, 06 Jan 2026 14:02:13 -0500 A.02931992 A.24986639 ESLA ESLAW O.00047082 O.00638906 O.52433315 http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) completed an $8.0 million registered direct offering and concurrent private placement that closed January 6, 2026, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor. The company also issued common warrants to purchase up to 7,594,935 shares of common stock in the concurrent private placement.</p> <p>The combined offering price was $1.58 per share and accompanying warrant, or $1.57999 for each pre-funded warrant and accompanying warrant. The pre-funded warrants carry an exercise price of $0.00001 per share and are exercisable immediately http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html Tue, 06 Jan 2026 14:02:13 -0500 A.02931992 A.24986639 ESLA ESLAW O.00047082 O.00638906 O.52433315 http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) completed an $8.0 million registered direct offering and concurrent private placement that closed January 6, 2026, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor. The company also issued common warrants to purchase up to 7,594,935 shares of common stock in the concurrent private placement.</p> <p>The combined offering price was $1.58 per share and accompanying warrant, or $1.57999 for each pre-funded warrant and accompanying warrant. The pre-funded warrants carry an exercise price of $0.00001 per share and are exercisable immediately http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html Tue, 06 Jan 2026 14:02:13 -0500 A.02931992 A.24986639 ESLA ESLAW O.00047082 O.00638906 O.52433315 http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) completed an $8.0 million registered direct offering and concurrent private placement that closed January 6, 2026, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor. The company also issued common warrants to purchase up to 7,594,935 shares of common stock in the concurrent private placement.</p> <p>The combined offering price was $1.58 per share and accompanying warrant, or $1.57999 for each pre-funded warrant and accompanying warrant. The pre-funded warrants carry an exercise price of $0.00001 per share and are exercisable immediately http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html Tue, 06 Jan 2026 14:02:13 -0500 A.02931992 A.24986639 ESLA ESLAW O.00047082 O.00638906 O.52433315 http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) completed an $8.0 million registered direct offering and concurrent private placement that closed January 6, 2026, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor. The company also issued common warrants to purchase up to 7,594,935 shares of common stock in the concurrent private placement.</p> <p>The combined offering price was $1.58 per share and accompanying warrant, or $1.57999 for each pre-funded warrant and accompanying warrant. The pre-funded warrants carry an exercise price of $0.00001 per share and are exercisable immediately http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html Tue, 06 Jan 2026 14:02:13 -0500 A.02931992 A.24986639 ESLA ESLAW O.00047082 O.00638906 O.52433315 http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) completed an $8.0 million registered direct offering and concurrent private placement that closed January 6, 2026, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor. The company also issued common warrants to purchase up to 7,594,935 shares of common stock in the concurrent private placement.</p> <p>The combined offering price was $1.58 per share and accompanying warrant, or $1.57999 for each pre-funded warrant and accompanying warrant. The pre-funded warrants carry an exercise price of $0.00001 per share and are exercisable immediately http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html Tue, 06 Jan 2026 14:02:13 -0500 A.02931992 A.24986639 ESLA ESLAW O.00047082 O.00638906 O.52433315 http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) completed an $8.0 million registered direct offering and concurrent private placement that closed January 6, 2026, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor. The company also issued common warrants to purchase up to 7,594,935 shares of common stock in the concurrent private placement.</p> <p>The combined offering price was $1.58 per share and accompanying warrant, or $1.57999 for each pre-funded warrant and accompanying warrant. The pre-funded warrants carry an exercise price of $0.00001 per share and are exercisable immediately http://www.streetinsider.com/Equity+Offerings/Estrella+Immunopharma+closes+%248+million+financing+round/25812368.html Tue, 06 Jan 2026 14:02:13 -0500 A.02931992 A.24986639 ESLA ESLAW O.00047082 O.00638906 O.52433315